Phase 3 data show consistent safety with repeat TrenibotE treatments, while survey findings highlight growing aesthetic demand among patients using GLP-1 weight loss drugs.
Allergan Aesthetics, an AbbVie company, presented four posters at the American Academy of Dermatology (ADD) Meeting, including new data on an investigational neurotoxin and insights into patients using GLP-1 agonists for weight loss.
“At Allergan Aesthetics, we are dedicated to scientific research that reinforces customer and patient trust and confidence in our broad product portfolio,” says John Maltman, PhD, vice president of global aesthetics medical affairs at Allergan Aesthetics, in a release. “Our data presented at AAD advance knowledge of our market-leading and emerging portfolio to deliver safe and effective treatments that address patients’ aesthetic concerns.”
Treatment With TrenibotE
One poster reported findings from an 18-week, open-label Phase 3 study evaluating repeat treatments of trenibotulinumtoxinE (TrenibotE) for glabellar lines. The study included up to three treatments and found a consistent safety profile across the study period.
TrenibotE is an investigational botulinum neurotoxin serotype E designed for rapid onset and shorter duration of effect. In the study, effects were observed as early as 8 hours after administration (the earliest assessment time), with a duration of approximately two to three weeks.
Key findings from the Phase 3 study include:
- TrenibotE was well tolerated across three sequential treatments, with no new safety concerns and no neutralizing antibody development
- Reductions in glabellar line severity were observed, with consistent efficacy across treatments based on investigator and participant assessments
Patient Trends Among GPL-1 Users
Separate data presented at the meeting examined aesthetic concerns among patients receiving GLP-1 agonists for weight loss. The findings were based on an electronic survey of US healthcare professionals with experience treating this patient population.
According to the survey, demand for aesthetic treatments among patients using GLP-1 therapies is increasing. An estimated 52% of these patients expressed concern about their facial appearance during treatment.
Additional findings include:
- Healthcare professionals reported that 32% of GLP-1-treated patients were new to their practice
- The most commonly cited barriers to treatment were cost (82%) and concern about unnatural results (58%)
- Patients were reported to be predominantly white (64%), female (70%), and between the ages of 30 and 49 (56%)
The company also presented additional posters on topics including a topical hydrating serum following hyaluronic acid injections and patient-reported outcomes for a neck treatment with VYC-12L.
TrenibotE remains investigational and has not yet received regulatory approval.
ID 135480953 © motortion | Dreamstime.com
